STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio Strengthens Board Commitment with Major Equity Grant to Director Dachille

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma Director Douglas A. Dachille reported multiple equity transactions on June 20, 2025:

  • Received 6,589 restricted stock units (RSUs) with $0 exercise price, vesting over three years through June 20, 2028
  • Granted 8,425 stock options with strike price of $41.73, vesting over three years and expiring June 19, 2035
  • Currently holds 20,000 shares indirectly through The Dachille 2012-1 Family Trust for his children's benefit

All equity grants are subject to continued service on BridgeBio's board of directors. The RSUs and options will vest in three equal annual installments starting June 20, 2025. These grants appear to be part of the company's standard director compensation under their 2021 Amended and Restated Stock Option and Incentive Plan.

Positive

  • None.

Negative

  • None.
Insider Dachille Douglas A.
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 8,425 $0.00 --
Grant/Award Common Stock 6,589 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 8,425 shares (Direct); Common Stock — 6,589 shares (Direct); Common Stock — 20,000 shares (Indirect, By The Dachille 2012-1 Family Trust)
Footnotes (1)
  1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, for which the reporting person's spouse is the trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dachille Douglas A.
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 6,589 A $0(2) 6,589 D
Common Stock 20,000 I By The Dachille 2012-1 Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $41.73 06/20/2025 A 8,425 (4) 06/19/2035 Common Stock 8,425 $0 8,425 D
Explanation of Responses:
1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, for which the reporting person's spouse is the trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
4. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Douglas A. Dachille 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many BBIO restricted stock units (RSUs) did Douglas Dachille receive on June 20, 2025?

Douglas Dachille received 6,589 restricted stock units (RSUs) on June 20, 2025, as part of BridgeBio's 2021 Amended and Restated Stock Option and Incentive Plan.

What is the vesting schedule for BBIO director Douglas Dachille's June 2025 stock options?

The stock options will vest over three years, with one-third vesting each year after June 20, 2025. All 8,425 shares underlying the stock options will be fully vested by June 20, 2028, subject to Dachille's continued service on BridgeBio's board of directors.

What is the exercise price of BBIO stock options granted to Douglas Dachille in June 2025?

The stock options were granted with an exercise price of $41.73 per share and have an expiration date of June 19, 2035.

How many BBIO shares does Douglas Dachille indirectly own through the Dachille 2012-1 Family Trust?

The Dachille 2012-1 Family Trust owns 20,000 shares of BBIO common stock. The trust is for the benefit of Dachille's children, with his spouse serving as trustee. Dachille disclaims beneficial ownership of these securities for Section 16 purposes.